MedPath

Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy

Conditions
Focal Epilepsy
Registration Number
NCT05497193
Lead Sponsor
Yang Xinwei
Brief Summary

This project is a multicenter prospective study. By retrieving outpatient medical records and collecting clinical data of epilepsy patients, the efficacy and safety of single-drug perampanel in patients with focal epilepsy were analyzed.

Detailed Description

This project is a multicenter prospective study. The selected case population was given the oral antiepileptic drug perampanel for 12 months, and the seizure control (complete control, markedly effective, effective, ineffective, worsening), EEG changes (normal, Effective, ineffective), and adverse reactions were analyzed, so as to provide a basis for perampanel monotherapy in children with focal epilepsy.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
280
Inclusion Criteria

(1) Clinical diagnosis of focal epilepsy; (2) Take anti-epileptic drugs as prescribed by your doctor; (3) Epilepsy patients diagnosed with focal epilepsy with or without generalized seizures, and Monitoring for ≥12 months; (4) Newly diagnosed epilepsy patients, or only taking 1-2 other AEDs, without regular antiepileptic treatment, the efficacy is not good, after using perampanel, gradually stop AEDs for 8 weeks. For perampanel monotherapy; (5) the number of seizures ≥ 1 in the first 3 months of enrollment.

Exclusion Criteria

(1) syncope (2) Pseudo-seizure(3)transient ischemic attack

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety after drug treatmentone year

Common adverse reactions include: dizziness, drowsiness, fatigue, irritability, nausea and falls and weight gain.

clinical efficacy after drug treatment:one year

Epilepsy seizures: the seizure frequency 3 months before treatment is the baseline, and the maintenance period is compared with the baseline. Complete control: no seizures after treatment; markedly effective: seizure frequency reduced by \> 75%; effective: seizure frequency reduced by \> 51%-74 %; Ineffective: frequency reduced by ≤50%, worsening: attack frequency increased by 25%.

EEG changes after drug treatmentone year

EEG changes: (1) normal EEG (2) abnormal EEG: including epileptiform discharge, background rhythm slowing, epileptiform discharge + background rhythm slowing. EEG judgment: (1) normal: the epileptiform discharge disappeared or the background slowing disappeared (2) effective: the epileptiform discharge was reduced or the background slowing was improved (3) invalid: the epileptiform discharge did not change or aggravate after the drug.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

XI Jing Hospital

🇨🇳

Xi'an, Shan XI, China

© Copyright 2025. All Rights Reserved by MedPath